GenomeDx Biosciences, Mayo Clinic deal

The partners expanded a 2009 deal to give GenomeDx exclusive, worldwide rights to develop and commercialize IP developed at the clinic. The deal also includes IP co-developed by the partners and continued access to the clinical data covering the hospital's cohort of prostate cancer samples to allow for longer-term follow up and evaluation of biomarkers. GenomeDx declined to disclose what the IP covers or the financial details, but the partners did say that the clinic has a financial interest in technology licensed to GenomeDx. ...